Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-02-05
2003-05-13
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S002600, C514S171000, C514S177000, C514S178000, C514S182000, C514S415000
Reexamination Certificate
active
06562790
ABSTRACT:
This invention relates to methods and products to abate coronary artery blockage in men and in women. These methods include administering a combination of natural hormones, including human growth hormone or recombinant human growth hormone, one or more sex hormones, such as testosterone, estrogen or progesterone and other naturally occurring hormones, as appropriate.
The methods and products of this invention are disclosed in part in U.S. Pat. No. 5,855,920, issued Jan. 5, 1999, entitled TOTAL HORMONE REPLACEMENT THERAPY. The entire text of the ′920 patent is incorporated herein by this reference. However, in abating coronary artery blockage in men and women, the methods of this invention additionally call for administering sufficient T3 thyroid supplement to maintain the body temperature of males and females with such blockage above about 97.6° F. upon awakening, and is in the range of about 98.7° F. to about 99.0° F. during the afternoon hours. In addition, in treating males with coronary artery blockage, and with below optimal testosterone levels, these methods call for administering natural testosterone in gel form, preferably applied topically to under arm pits.
REFERENCES:
patent: 4727041 (1988-02-01), Aroonsakul
patent: 4791099 (1988-12-01), Aroonsakul
patent: 4897389 (1990-01-01), Aroonsakul
patent: 4898856 (1990-02-01), Aroonsakul
patent: 4898857 (1990-02-01), Aroonsakul
patent: 4902680 (1990-02-01), Aroonsakul
patent: 5017470 (1991-05-01), Aroonsakul
patent: 5391381 (1995-02-01), Wong et al.
patent: 5397771 (1995-03-01), Bechgaard et al.
patent: 5424199 (1995-06-01), Goeddel et al.
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5550107 (1996-08-01), Labrie
patent: 5563131 (1996-10-01), Berliner et al.
patent: 5691169 (1997-11-01), Dalbage et al.
patent: 5691325 (1997-11-01), Sandyk
patent: 5855920 (1999-01-01), Chein
Buerke et al. “Cardioprotective effect of insulin-like growth factor I in myocardial ischemia by reperfusion,” 1995, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 8031-8035.*
Isselbacher et al. ‘Harrison's Principles of Internal Medicine,’ 13th Edition, p. 81, McGraw Hill Inc., 1994.*
Advanced Medical Therapy: Human Growth Hormone Replacement Therapy In Adults, Edward M. Lichten, M.D., P.C. (1997).
PCT: WO 95/32991 (FAHY) See especially p. 4, line 4-14 (against claims 21-30).
“Administration of Human Somatotropin in Levodopa-Treated Patients With Parkinsonism” by Paul S. Papavasiliou et al.,Arch Neurol, vol. 36, Oct. 1979.
“Long-Term Influence of Levodopa on Bone Mass and Growth Hormone in Postmenopausal Women with Parkinson's Disease” by H. Rico, et al.,Clinical Neuropharmacology, vol. 10, No. 1, pp. 87-91, 1987.
“Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease” by Bonnie M. Davis, MD, et al.,Journal of the American Geriatrics Society, vol. 33, No. 11.
“Disturbances of Pituitary Function in Central Nervous System Disease” by Glenn T. Peake, MD, et al.,Medical Clinics of North America, vol. 52, No. 2, Mar. 1968.
“Growth Hormone Response in Parkinson's Disease” by J.D. Parkes, et al.,The Lancet, Feb. 28, 1976.
“Blood Levels of FSH, LH, TSH, And GH in Parkinsonian patients Before and During L-Dopa Treatment” by P.O. Lundberg,Acta Neurol. Scandinav., vol. 48, pp. 427-432, 1972.
“Therapeutic Approaches in Parkinson's Disease: Possible Roles of Growth Hormone and Somatostatin” by George C. Cotzias, et al.,The Basal Ganglia, 1976.
“Effects of Estrogen, Progestin and Combined Estrogen-Progestin Oral Contraceptive Preparations on Experimental Allergic Encephalomyelitis” by Barry G. Arnason et al., Boston, MA.
“Molecular Biology of Neurological and Psychiatric Disorders. I. Effect of Parkinsonism, Age, Sex and L-Dopa on Platelet Monoamine Oxidase” by E.A. Zeller, et al.,Journal of Neutral Transmission, 39, pp. 63-77, 1976.
“Peliosis Hepatis Report of Nine Cases” by Tsutomu Karasawa, et al.,Acta Path. Jap., 29(3), pp. 457-469, 1979.
“Orale Ovulationshemmer—Indikationen und Komplikationen aus Neurologischer Sicht” by Sigrid Poser,Fortschr. Neurol. Psychiat., 45, 1977.
“Contraccezione Orale e Sclerosi Multipla” by A. Ghezzi, et al.,Archivio per le Scienze Mediche, 136, 1979.
“Estrogens and Extrapyramidal System” by P. Bedard, et al.,The Lancet, Dec. 24 & 31, 1977.
“Etudes des Androgenes Plasmatiques Chez les Femmes Atteintes de Maladies Auto-Immunes” by M. Dougados, et al.,Revue du Rhumatisme, 1984, 51(3), pp. 145-149.
“Observations in a Preliminary Open Trial of Estradiol Therapy for Senile Dementia-Alzheimer's Type” by Howard Fillit, et al.,Psychoneuroendocrinology, vol. 11, No. 3, pp. 337-345, 1986.
“Metabolic Effects of GH: A Rationale for Continued GH Treatment of GH-Deficient Adults After Cessation of Linear Growth” by A. Juul, et al., Department of Growth and Reproduction, University of Copenhagen, Denmark.Horm Res(Switzerland) 1995, 44 Suppl 3, pp. 64-72, ISSN 0301-0163, Journal Code GBI.
“Insulin-Like Growth Factor I Alters Peripheral Thyroid Hormone Metabolism in Humans: Comparison with Growth Hormone” by M.A. Hussain, et al., Division of Endocrinology and Metabolism, University Hospital of Zurich,Switzerland.Eur J Endocrinol(Norway) May 1996, 134 (5) pp. 563-567, ISSN 0804-4363, Journal Code BXU.
“Improved Final Height in Girls with Turner's Syndrome Treated with Growth Hormone and Oxandrolone” by K.O. Nilsson, et al., Department of Pediatrics, University Hospital Malmo, Sweden,J. Clin Endocrinol Metab(United States) Feb. 1996, 81(2) pp. 635-640, ISSN 0021-972X, Journal Code HRB.
“Insulin, Insulin-Like Growth Factor-Binding Protein-1, and Sex Hormone-Binding Globulin in Patients with Turner's Syndrome: Course Over Age in Untreated Patients and Effect of Therapy with Growth Hormone Alone and in Combination with Oxandrolene” by G. Haeusler, et al., Pediatric Department, University of Vienna, Austria.J Clin Endocrinol Metab(United States) Feb. 1996, 81(2) pp. 536-541, ISSN 0021-972X, Journal Code HRB.
“Growth Hormone Deficiency in Adults: Characteristics and Response to Growth Hormone Replacement” by S.A. Lieberman, et al., Department of Internal Medicine, University of Texas Medical Branch, Galveston, 77555-1060, USA.J Pediatr(United States) May 1996. 128 (5 Pt 2) pS58-60, ISSN 0022-3476, Journal Code JLZ.
“Effect of Anabolic Hormones and Insulin-Like Growth Factor-I on Muscle Mass and Strength in Elderly Persons” by W.J. Carter, et al., Memorial Veterans Hospital, Little Rock, Arkansas, USA.Clin Geriatr Med(United States) Nov. 1996, 11(4) p735-48, ISSN 0749-0690, Journal Code CLN.
“Screening for PIT1 Abnormality by PCR Direct Sequencing Method” by Y. Irie, et al., Department of Laboratory Medicine, Osaka University Medical School, Japan.Thyroid(United States) Jun. 1995, 5(3) p207-11, ISSN 1050-7256, Journal Code BJW.
“Trophic Factor Supplementation: Effect on the Age-Associated Changes in Body Composition” by R.S. Schwartz, et al., Division of Gerontology and Geriatric Medicine, Harborview Medical Center, Seattle, USA.J Gerontol A Biol Sci Med Sci(United States) Nov. 1995, 50 Spec No p151-6, ISSN 1079-5006, Journal Code CBA.
“Treatment of Growth Hormone-Deficient Adults with Recombinant Human Growth Hormones Increases the Concentration of Growth Hormone in the Cerebrospinal Fluid and Affects Neurotransmitters” by J.O. Johansson, et al., Department of Internal Medicine, University of Goteborg, Sweden.Neuroendocrinology(Switzerland) Jan. 1995, 61(1) p57-66, ISSN 0028-3835, Journal Code NY8.
“Adult Growth Hormone Deficiency” by J.O. Jorgensen, et al., Medical Department M (Endocrinology and Diabetes), Aarhus Kommunehospital, Denmark.Horm Res(Switzerland) 1994, 42(4-5) p235-41, ISSN 0301-0163, Journal Code GBI.
“Effects of Recombinant Human Growth Hormone on Metabolic Indices, Bodycomposition, and Bone Turnover in Health Elderly Women” by L. Holloway, et al., Aging Study Unit, Palo Alto Veterans Affairs Medical Center, California 94304.J Clin Endocrinol Metab(United States) Aug. 1994, 79(2) p470-9, ISSN 0021-972X, Journal Code HRB.
“Treatment of Growth Delay in Boys With Isolated Growth Hormon
Bright Patrick F.
Bright & Lorig
Travers Russell
Wang Shengjun
LandOfFree
Hormone therapy methods and hormone products for abating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hormone therapy methods and hormone products for abating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hormone therapy methods and hormone products for abating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3068933